Alligator Bioscience has received the SwedenBIO Award for ”exceptional achievements within the life-science industry”. This is yet another confirmation of Alligator´s success in the field. Alligator is a privately held Swedish biotech company with a pipeline of immune-activating antibodies for tumor-directed immunotherapy of cancer. Notably, in 2015 Alligator granted Janssen Biotech Inc, one of the Janssen Pharmaceutical companies of Johnson & Johnson, an exclusive, worldwide license to Alligator’s clinical candidate ADC-1013. Under the agreement Alligator receives an initial up-front payment and aggregated future milestones up to a potential total of 700 MUSD.